AI in Healthcare

Today's Stories

1. 1

   J&J uses AI to transform healthcare from New Jersey

   Johnson & Johnson is applying AI and machine learning across its healthcare work, from drug discovery and clinical trials to surgical training and supply chain predictions. The company says AI, combined with science and people, can transform healthcare rather than just improve it incrementally, and it is supporting New Jersey's AI Hub efforts with government and academia.

   J&J's AI tools help surgeons analyze patient anatomy, recommend instruments, and provide post-case reviews, while also improving supply and demand forecasting for hospitals and clinics.

2. 2

   Danaher Expands AI-Driven R&D with Genedata-Abcam

   Genedata, a Danaher company, announced an expanded collaboration with Abcam to deploy Genedata Biologics across Abcam's global R&D operations. The goal is to strengthen antibody development, enhance data connectivity, and accelerate AI-enabled innovation. This internal partnership reinforces Danaher's push into AI-enabled R&D but does not materially change near-term catalysts, which still depend on bioprocessing and diagnostics demand. Key risks remain, including China policy pressures and exposure to funding-sensitive early-stage biotech customers.

   Julie Sawyer Montgomery is set to become Danaher's CEO from October 2026. Her background in diagnostics and scaling businesses may shape how the company prioritizes AI-enabled platforms, consumables growth, and cost productivity initiatives.

3. 3

   RIZAP accidentally uploads IHI Health Insurance Union member data to generative AI

   RIZAP accidentally uploaded member information of IHI Health Insurance Union to a generative AI service. The incident affects 210 people and includes disease-related information. This is a privacy breach involving sensitive health data. The affected individuals are members of a corporate health insurance union, and the leaked information includes medical conditions, making the incident particularly serious.

   The article does not specify how the upload occurred, whether the data was exposed externally, or what steps RIZAP is taking in response. Further details may emerge as the situation develops.

4. 4

   Chai Discovery partners with Bristol Myers Squibb for AI antibody drug discovery

   Chai Discovery announced a partnership with Bristol Myers Squibb (BMS) on August 20, 2026, to develop AI-driven therapeutic antibodies. BMS gains access to Chai's advanced AI models and platform, including molecular folding and design models, potentially accelerating antibody drug discovery.

   The collaboration aims to leverage AI to create therapeutic antibodies, which could reshape how antibody drugs are discovered and developed.

5. 5

   Aetna CEO: AI Makes Healthcare Simpler for Members

   Aetna, the health benefits business of CVS Health, has rebuilt its cost-estimation product to cover more than 20,000 medical services, allowing members to use natural language and AI to estimate costs before receiving care. This shift has led to a major behavioral change: usage of the cost-estimation tool has risen from below 10% to nearly 70% among people using the capability before a procedure, reflecting a focus on member experience over traditional insurer priorities.

   Aetna evaluates such products not just on customer metrics but on whether they help members obtain preventative care, avoid emergency room visits, or prevent more complex procedures, with the goal of making coverage, pharmacy, and care feel like one connected journey.

6. 6

   AI-driven drug discovery hinges on 'enterprise intelligence'

   A forum report from Nikkei Biotech ONLINE argues that competitiveness in drug discovery and biotech will be decided by enterprise intelligence, not just AI data. The report suggests that companies that build organizational AI capabilities, rather than simply accumulating data, will lead in this space.

   The article is an event report, not a study; the claim is an argument about the future of the sector's competitiveness.